Treasury's Proposed China Investment Rule Sparks Debate Over Licensing Exemptions

The U.S. Treasury Department recently proposed a rule that would limit American investment in Chinese biotechnology companies, prompting immediate discussion among industry stakeholders.

Commentators are weighing whether the measure should be viewed as an offensive strategy to boost domestic R&D or a defensive effort to curb China’s biotech progress, and questioning how effective such limits could be.

A Treasury official clarified that licensing agreements are exempt from the proposed restrictions, a point that has become central to the ongoing disagreement about the rule’s overall impact.